

Butacote : today's way to rheumatic pain release.

Contributors

Geigy Pharmaceuticals

Publication/Creation

[1975?]

Persistent URL


<https://wellcomecollection.org/works/jfusvf69>

License and attribution

Conditions of use: it is possible this item is protected by copyright and/or related rights. You are free to use this item in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s).



Wellcome Collection
183 Euston Road
London NW1 2BE UK
T +44 (0)20 7611 8722
E library@wellcomecollection.org
<https://wellcomecollection.org>



Butacote[®] **today's way** **to rheumatic** **pain release**

Specifically formulated
Stringently tested
Clinically assessed

Achieves consistent and reliable therapeutic
blood levels which ensure...

Prompt and sustained relief from pain

Powerful anti-inflammatory activity


Significant reduction in morning stiffness

Improved joint mobility

Availability

As enteric coated tablets (pale-violet and imprinted
Geigy) containing 4-butyl 1,2-diphenyl-pyrazolidine-3,
5-dione (Phenylbutazone B.P.) 100mg or 200mg

Geigy



Butacote[®]

An appraisal from published clinical trials

Prompt and sustained relief from pain
Improved joint mobility
Significant reduction in the duration
and severity of morning stiffness

Effectiveness:

"Butacote is significantly better than either Ibuprofen or Placebo in relieving pain, stiffness and improving symptoms."¹

Gastric Tolerant:

"Many patients with gastric intolerance to other preparations, even when intolerant to several preparations, can be expected to tolerate Butacote over long periods of treatment."²

Patient and Doctor Preference:

Both patients and doctors prefer Butacote to standard phenylbutazone.³

References:

1. J. Inter. Med. Res. Vol. 2 No. 2. (1974)
2. Clin. Trials J. Vol. 9 No. 1. (1972)
3. The Practitioner, 206 671 (1970)